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ABSTRACT
We report a case of GCTB in an 84-year-old Japanese 
man who had a tumor in his left iliac bone and was 
treated safely with denosumab. The patient noticed a 
painful mass, with gradual enlargement, in his left low 
back next to the iliac region. Magnetic resonance imag-
ing revealed that the tumor measured 94 × 66 × 90 mm 
and was located in the left iliac bone. Histologically, 
the tumor was composed of proliferative oval-shaped 
mononuclear cells, admixed with large number of 
osteoclast-like giant cells. Immunohistochemically, a 
strong positivity for histone 3.3 G34W mutant protein 
was observed in the nuclei of the mononuclear cells, 
confirming the diagnosis of GCTB. Because it was con-
sidered as unresectable tumor, the patient was treated 
with denosumab without any side effects.
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Giant cell tumor of bone (GCTB) is a benign but locally 
aggressive primary bone neoplasm. GCTB represents 
4-5% of all primary bone tumors. The peak incidence is 
between the ages of 20 and 45 years.1, 2 In addition, the 
treatment of GCTB has changed dramatically since the 
availability of denosumab in recent years. Denosumab, a 
monoclonal antibody specific for a receptor activator of 
nuclear factor kappa-B ligand (RANKL), has attracted 
attention as a novel therapeutic strategy for GCTB. In 
particular, denosumab has become an extremely useful 
treatment for unresectable GCTB. Here, we described a 
case of GCTB in an 84-year-old Japanese man who had 
a tumor in his left iliac bone, which was treated with 
denosumab.
PATIENT REPORT
An 84-year-old Japanese man without a history of any 
previous traumatic episodes, noticed a painful mass in 
the left low back region. The mass gradually enlarged 
over a period of two months. The patient was referred to 
our hospital for evaluation and treatment by his primary 
care doctor. Physical examination showed that the mass 
was a tumor localized to the left low back in the iliac 
region, of about 8 cm in diameter, hard and unmovable 
with mild tenderness. No abnormality was observed in 
the skin. The patient had a medical history of diabetes 
mellitus and chronic renal failure. His family history 
was unremarkable. Laboratory analysis revealed that 
white blood cell counts and lactate dehydrogenase levels 
were normal, alkaline phosphatase level was 514 U/L 
(normal range: 106-332 U/L), Serum calcium level was 
8.9 mg/dL (normal range: 8.8–10.1 mg/dL), blood urea 
nitrogen was 22.0 mg/dL (normal range: 8-20 mg/dL), 
creatinine was 1.16 mg/dL (normal range: 0.65–1.07 mg/
dL), C-reactive protein was 0.66 mg/dL (normal level < 
0.15 mg/dL), hemoglobin A1C level was 6.9% (normal 
range: 4.9–6.0%), and tartrate-resistant acid phospha-
tase 5b (TRACP-5b) was 1500 mU/dL or higher (normal 
range: 170–590 mU/dL). Plain radiography showed an 
expansile osteolytic lesion with partial marginal sclero-
sis in the left iliac bone (Fig. 1). Computed tomography 
(CT) also revealed a ballooning osteolytic lesion involv-
ing soft tissues and the sacroiliac joint with a partially 
lacking sclerotic rim (Fig. 2A). The tumor demonstrated 
an abnormal uptake of 2-[18 F] fluoro-2 deoxy-D glu-
cose (FDG) on positron emission tomography (PET)-
CT, with a maximum standardized uptake value of 11.4 
(Fig. 2B). Magnetic resonance imaging (MRI) revealed 
that the tumor measured 94 × 66 × 90 mm, was located 
in the left iliac bone invading the gluteus maximus, 
gluteus medius, paravertebral muscle, and sacral bone 
through the sacroiliac joint. It was partially lobulated 
and displayed a relatively clearly defined margin (Fig. 
3). T1-weighted imaging exhibited iso~low-signal 
intensity in the tumor region (Fig. 3A). In contrast, T2-
weighted imaging exhibited inhomogeneous high signal 
intensity within low signal intensity of the tumor (Fig. 
3B). Enhanced MRI exhibited inhomogeneous enhance-
ment within the lesion (Fig. 3C). Whole body PET-CT 
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showed no evidence of another tumor.
Based on the clinical findings and imaging ex-
amination, we initially considered this tumor to be a 
malignant tumor such as metastatic bone tumor of an 
unknown primary origin and primary bone sarcoma; 
however, an option of GCTB was also included 
in the differential diagnosis. A core needle biopsy 
was performed for histological examination, which 
revealed a giant cell-rich lesion. Although GCTB was 
suspected, it was difficult to exclude other neoplastic/
nonneoplastic lesions such as giant cell reparative 
granuloma, giant cell-rich osteosarcoma, and giant cell 
variant of undifferentiated pleomorphic sarcoma of 
bone. Thereafter, an open biopsy was performed and 
a yellow lesion with an elastic-soft consistency was 
obtained. Histological examination showed a tumor 
similar to that in the initial biopsy, composed of oval-
shaped mononuclear cells admixed with a large number 
of osteoclast-like giant cells (Figs. 4A and B). The giant 
cells were evenly distributed within the lesion and had 
a variable number of nuclei (up to 50) and abundant 
eosinophilic cytoplasm. Mitotic cells were occasionally 
observed among the mononuclear cells (up to 2/high 
power field) but these were never atypical. Marked 
nuclear pleomorphism and hyperchromasia were not ob-
served. Immunohistochemistry using an anti-histone 3.3 
G34W mutant antibody (clone RM263; dilution, 1:100; 
RevMAb Biosciences, South San Francisco, CA) was 
performed, and a strong positive staining in the nucleus 
was observed in the mononuclear cells (Fig. 4C). The 
tumor was finally diagnosed definitively as GCTB of 
the iliac bone based on the clinical, histological, and 
immunohistochemical examinations.
We considered that surgery would be associated 
with high risks after evaluating the patient’s age, tumor 
size, anatomical location, and functional loss due to 
surgery. Therefore, we administered a treatment with 
denosumab, a monoclonal antibody specific to RANKL. 
The patient received a subcutaneous injection of de-
nosumab (120 mg) on days 0, 7, 14, 28, and thereafter, 
every four weeks concomitantly taking orally daily 
supplements containing calcium and magnesium. The 
patient received a total of 11 subcutaneous injections 
Fig. 2. (A) Plain CT reveals that the tumor has a ballooning osteolytic lesion involving soft tissues and the sacroiliac joint with a partially 
lacking sclerotic rim. (B) The maximum standardized uptake value of the tumor was 11.4 on positron emission tomography-CT. CT, 
computed tomography.
Fig. 1. Plain radiography of the pelvis showing an expansile 
osteolytic lesion with a partial marginal sclerosis in the left iliac 
bone.
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of denosumab in ten months and this treatment is still 
ongoing as of now. The patient’s pain has gradually 
improved. Plain radiography showed a structure of a 
soap bubble appearance with marginal ossification in 
the expansile lesion in the left iliac bone (Fig. 5). In CT 
imaging, the tumor size appeared slightly decreased, 
and the ossification of the tumor rim became remarkable 
(Fig. 6). After four cycles of subcutaneous injections of 
denosumab, TRACP-5b levels decreased to normal val-
ues (119 mU/dL) and remained within the normal range 
over the next nine months. Serum calcium levels were 
normal throughout the treatment. The patient had expe-
rienced none of the known side effects of denosumab. 
The present course of treatment has been uneventful, 
with no evidence of recurrence or metastasis.
DISCUSSION
GCTB is a benign but locally aggressive primary bone 
neoplasm and represents 4–5% of all primary bone 
tumors. The peak incidence is between the ages of 
20 and 45 years.1, 2 GCTB is very unusual in patients 
older than age 55.1 The occurrence of GCTB in patients 
who are 55 years of age and older is well documented, 
comprising approximately 1.6% to 35% of case series 
in international population-based studies.3–16 There are 
two main previously published reports that described 
GCTB in elderly patients.17, 18 McCarthy et al.17 reported 
ten such cases of patients whose age ranged from 62 to 
78 years. They concluded that the behavior of GCTB 
in elderly patients was similar to that of lesions in the 
more commonly involved younger patients. Broehm et 
al.18 reported 34 such cases in patients ranging in age 
Fig. 3. Representative MRI images. The tumor is localized to 
the left iliac bone involving the gluteus maximus, gluteus medius, 
paravertebral muscle, and sacral bone through the sacroiliac joint 
(white arrows). (A) T1-weighted image exhibits iso~low-signal 
intensity. (B) T2-weighted image exhibits inhomogeneous high 
signal intensity within low signal intensity. (C) Enhanced MRI 
exhibits inhomogeneous enhancement. MRI, magnetic resonance 
imaging.
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Fig. 4. Histology and immunohistochemistry of the tumor. 
Staining methods include (A), (B), hematoxylin and eosin, and 
(C), immunohistochemistry using an antibody against histone 
3.3 G34W. (A) Oval-shaped mononuclear cells are admixed 
within a large number of osteoclast-like giant cells (scale bar: 100 
μm). (B) At high-power magnification, the giant cells having a 
variable number of nuclei (up to 50) and abundant eosinophilic 
cytoplasm are observed (scale bar: 20 μm). They are not atypical, 
and the marked nuclear pleomorphism and hyperchromasia are 
not observed. (C) A positive signal for histone 3.3 G34W in the 
mononuclear cells.
Fig. 5 . Plain radiography of the pelvis ten months after starting 
the treatment shows a structure with a soap bubble appearance with 
marginal ossification in the expansile lesion.
Fig. 6. CT imaging ten months after starting treatment revealed 
that the tumor size was slightly decreased and the ossification 
of the tumor rim became remarkable, especially, on the lesion 
involving the sacrum (white arrows) compared with that before 
treatment. CT, computed tomography.
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from 56 to 83 years. They demonstrated that fibrosis 
and reactive bone were common, potentially leading 
to diagnostic confusion of GCTB in elderly patients. 
Cytogenetically, GCTB has recently been shown to 
harbor H3F3A (histone 3.3) mutations in virtually all 
cases (96%), with G34W accounting for the vast major-
ity of the mutant variants, and immunohistochemical 
detection of the G34W mutant in the nuclei of the 
mononuclear cells has been shown to be a powerful 
adjunct assay in the diagnosis of GCTB.19 The utility of 
histone 3.3 G34W immunohistochemistry was further 
confirmed by the present case, in which the patient’s age 
was very unusual for GCTB occurrence.
Until recently, there was no method for GCTB 
treatment other than surgery, but the availability of 
denosumab has dramatically changed this treatment 
strategy. Denosumab (anti-RANKL antibody) is a novel 
agent, a fully human monoclonal antibody that inhibits 
osteoclastic-medicated bone resorption by binding to 
osteoblast-produced RANKL. By this mechanism, de-
nosumab induces tumor reduction and bone reformation 
in patients with GCTB.20 Denosumab has proven to be 
a very effective treatment for unresectable GCTB.
The present case was a GCTB in an 84-year-old 
man. Because of the atypical age at the onset, a defini-
tive diagnosis of GCTB was made with care. Histone 
3.3 G34W immunostaining was especially useful for 
diagnosis. Because the tumor was huge and located in 
the iliac bone, we judged it unresectable and treated it 
with denosumab. Denosumab was effective and safe to 
use without any side effects. The patient presented in 
this case is thought to belong to the oldest age group of 
GCTB patients, and to the best of our knowledge, he is 
the oldest among patients with GCTB whose diagnosis 
was molecularly-confirmed by the detection of histone 
3.3 mutants. The oldest patient with GCTB was 88 
years old, reported by Amelio et al. in a population-
based study of 310 patients in Sweden.3 However, the 
site of tumor occurrence and the treatment strategy of 
that patient was not indicated and is currently unknown.
Ancillary testing for histone 3.3 G34W by immu-
nohistochemistry was a useful adjunct assay for the suc-
cessful diagnosis of GCTB. Although they may be rare, 
GCTB should be considered in the differential diagnosis 
of bone tumors for the elderly. Additionally, the present 
case highlights the efficacy and safety of denosumab 
treatment in elderly patients with GCTB.
Consent for publication: The patient was fully informed that his 
data would be submitted for publication.
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